Search
Isoetharine
go.drugbank.com/drugs/DB00221ApprovedIsoetharine is a relatively selective beta-2 adrenergic agonist. It is a catechol-like agent. Isoetharine is a fast-acting bronchodilator used for emphysema, bronchitis and asthma.
Basic Fibroblast Growth Factor
go.drugbank.com/drugs/DB14131InvestigationalSeveral different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. … The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages.
beta-Hydroxyisovaleric acid
go.drugbank.com/drugs/DB15344Investigationalbeta-Hydroxyisovaleric acid is under investigation in clinical trial NCT03018496 (Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.).
Typhoid Vaccine Live
go.drugbank.com/drugs/DB11050ApprovedInvestigationalThe vaccine prevents the development of typhoid fever, an acute, febrile enteric disease caused by *Salmonella typhi* by inducing a local immune response in the intestinal tract.
Obinepitide
go.drugbank.com/drugs/DB05045ExperimentalThese hormones are known to play a role in the regulation of food intake and appetite in man as satiety signal from the GI-tract to the CNS. … In obinepitide, the properties of both of these hormones have been implanted into a single molecule.
Cefamandole
go.drugbank.com/drugs/DB01326ApprovedWithdrawnIt is no longer marketed in the United States.
Synonyms: 7-D-MANDELAMIDO-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-3-CEPHEM-4-CARBOXYLIC ACID, (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acidQuinacrine
go.drugbank.com/drugs/DB01103InvestigationalAn acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. … It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigationalA265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate